NextCure Stock Forecast, Price & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NXTC stock has decreased by 75.0% and is now trading at $9.57.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.03. NextCure had a negative net margin of 65.22% and a negative return on equity of 8.43%.
View NextCure's earnings history.

9 analysts have issued 1-year price targets for NextCure's shares. Their forecasts range from $11.00 to $87.00. On average, they expect NextCure's stock price to reach $32.70 in the next twelve months. This suggests a possible upside of 241.7% from the stock's current price.
View analysts' price targets for NextCure.

NextCure saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,970,000 shares, an increase of 8.8% from the August 15th total of 1,810,000 shares. Based on an average daily trading volume, of 857,800 shares, the short-interest ratio is currently 2.3 days. Approximately 12.1% of the shares of the company are sold short.
View NextCure's Short Interest.

Some companies that are related to NextCure include Constellation Pharmaceuticals (CNST), Retrophin (RTRX), I-Mab (ARQT), Legend Biotech (PLRX), Gossamer Bio (GOSS), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), RAPT Therapeutics (RAPT), Passage Bio (KROS), Akouos (AKUS), Vectura Group (VEGPF), Morphic (MORF), Provention Bio (PRVB), Frequency Therapeutics (FREQ) and VBI Vaccines (VBIV).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Kadmon (KDMN), Novan (NOVN), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (3.63%), Cormorant Asset Management LP (2.52%), Hillhouse Capital Advisors LTD. (2.32%), Jennison Associates LLC (1.69%), Matthews International Capital Management LLC (0.92%) and Federated Hermes Inc. (0.41%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Great Point Partners LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cormorant Asset Management LP, and Nuveen Asset Management LLC.
View insider buying and selling activity for NextCure.

NXTC stock was acquired by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Federated Hermes Inc., Point72 Asset Management L.P., Asymmetry Capital Management L.P., Two Sigma Advisers LP, SG Americas Securities LLC, Swiss National Bank, and Vident Investment Advisory LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $9.57.

NextCure has a market capitalization of $263.34 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]